---
schema_version: "secwatch.filing_event.v1"
accession: "0001367644-23-000004"
form_type: "8-K"
ticker: "EBS"
cik: "0001367644"
company_name: "Emergent BioSolutions Inc."
filed_at: "2023-01-09T23:59:59+00:00"
generated_at: "2026-06-20T17:36:37.281197+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Emergent BioSolutions preliminary 2022 rev down 38%, adj net loss $70-90M, cuts 5% workforce, exec departures

## Summary
- Preliminary 2022 revenue $1.1-1.12B, down 38% YoY; adj net loss $70-90M; adj EBITDA $20-40M.
- Restructuring eliminates 132 roles (5% workforce) with $9-11M charges in Q1 2023; annual savings >$60M.
- EVP Katy Strei (CPO) and EVP Atul Saran (CSDO) to depart March 17; Michelle Pepin promoted to CHRO.
- Paul Williams appointed SVP Products Business leading MCM and NARCAN; Kelly Warfield leads new S&D function.
- 2023 financial outlook deferred to late February 2023.

## SEC filing metadata
- accession: 0001367644-23-000004
- form_type: 8-K
- ticker: EBS
- cik: 0001367644
- company_name: Emergent BioSolutions Inc.
- filed_at: 2023-01-09T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 2.05, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1367644/000136764423000004/0001367644-23-000004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1367644/000136764423000004/ebs-20230109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001367644-23-000004
- JSON: https://secwatch.observer/filing/0001367644-23-000004.json
- Plain text: https://secwatch.observer/filing/0001367644-23-000004.txt

## Key facts
- Earnings Releases
  Emergent BioSolutions Inc. reported full-year 2022 results: revenue $1,100-$1,120 million, net income $(210)-$(190) million.
  - Period: full-year 2022
  - Revenue: $1,100-$1,120 million
  - Net income: $(210)-$(190) million
  - Result: preliminary results
  source text: Total revenues for 2022 are expected to be in the range of $1,100 million to $1,120 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1367644/000136764423000004/0001367644-23-000004-index.htm
- Executive change
  Paul Williams was appointed as Senior Vice President Products Business at Emergent BioSolutions Inc..
  - Action: appointed
  - Role: Senior Vice President Products Business
  source text: The Company also announced the appointment of Paul Williams as the Company’s Senior Vice President Products Business, reporting to the Company’s CEO, Robert Kramer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1367644/000136764423000004/0001367644-23-000004-index.htm
- Executive change
  Atul Saran departed as Chief Strategy and Development Officer at Emergent BioSolutions Inc..
  - Action: will cease employment
  - Role: Chief Strategy and Development Officer
  source text: Atul Saran, the Company’s Chief Strategy and Development Officer, will cease employment with the Company on or about March 17, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1367644/000136764423000004/0001367644-23-000004-index.htm
- Restructurings & Charges
  Emergent BioSolutions Inc. announced a restructuring with charges of $9.0M to $11.0M affecting the Company (approximately 5 percent).
  - Type: restructuring
  - Charge: $9.0M to $11.0M
  - Affected area: the Company
  - Headcount: approximately 5 percent
  source text: On January 9, 2023, the Company also announced an organizational restructuring plan (the “Plan”) intended to reduce operating costs, improve operating margins, and continue advancing the Company’s ongoing commitment to profitable growth. The Plan includes a reduction of the Company’s current workforce by approximately 5 percent.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1367644/000136764423000004/0001367644-23-000004-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.